Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02194387 | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | active not recruiting | N/A | 337 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02324387 | Tc99m Sestamibi Molecular Breast Imaging | active not recruiting | N/A | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03624543 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | active not recruiting | Phase 2 | 51 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05165225 | Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | active not recruiting | Phase 2 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05677048 | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | active not recruiting | N/A | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05751668 | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) | active not recruiting | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06291324 | WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment | active not recruiting | — | 46 | Wake Forest University Health SciencesOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06584396 | Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study | active not recruiting | — | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02453620 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04993313 | Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study | active not recruiting | N/A | 62 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | active not recruiting | Phase 1 | 190 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT05809752 | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) | active not recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05825482 | Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout® | active not recruiting | N/A | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06336538 | Abbreviated MBCT for Depression in Older Black or African American Breast Cancer Survivors | active not recruiting | N/A | 23 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07137468 | Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk | active not recruiting | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07821229 | Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer(MCarb-T) | active not recruiting | N/A | 30 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00099437 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.(CONFIRM) | active not recruiting | Phase 3 | 736 | AstraZenecaINDUSTRY | 17 | Sep 14, 2026 | clinicaltrials |
| NCT03359954 | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04266249 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | active not recruiting | Phase 2 | 2,175 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04316117 | Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study | active not recruiting | Phase 2 | 138 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 14, 2026 | clinicaltrials |
| NCT05130580 | Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction | active not recruiting | N/A | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05262400 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 235 | PfizerINDUSTRY | 9 | Sep 14, 2026 | clinicaltrials |
| NCT05710328 | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial | active not recruiting | Phase 2 | 235 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT03147287 | Palbociclib After CDK and Endocrine Therapy (PACE) | active not recruiting | Phase 2 | 220 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120) | active not recruiting | Phase 2 / Phase 3 | 325 | Hoffmann-La RocheINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT04739696 | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.(eCare) | active not recruiting | N/A | 538 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04905082 | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | active not recruiting | N/A | 465 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05870579 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | active not recruiting | Phase 1 | 28 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 11, 2026 | clinicaltrials |
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.(NeoB-Cap1) | active not recruiting | Phase 1 / Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT06429761 | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients(STRIDE) | active not recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07238023 | Promoting Active Living Among People With Advanced Cancer | active not recruiting | N/A | 36 | University of OklahomaOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01351909 | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03964532 | TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05196269 | Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.(CINDERELLA) | active not recruiting | N/A | 1,030 | Fundacao ChampalimaudOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT05852691 | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 83 | Hoffmann-La RocheINDUSTRY | 16 | Sep 10, 2026 | clinicaltrials |
| NCT06561607 | A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | active not recruiting | Phase 3 | 542 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01182506 | Rehabilitation of Cognitive Changes in Breast Cancer Survivors | active not recruiting | N/A | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04001829 | Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | active not recruiting | Phase 2 | 249 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04030507 | Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer | active not recruiting | N/A | 214 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05226871 | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | active not recruiting | Phase 2 | 35 | PfizerINDUSTRY | 7 | Sep 9, 2026 | clinicaltrials |
| NCT05595577 | Improving Exercise Capacity With a Tailored Physical Activity Intervention(PALS) | active not recruiting | N/A | 105 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06057610 | A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | active not recruiting | Phase 3 | 868 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 74 | PfizerINDUSTRY | 9 | Sep 9, 2026 | clinicaltrials |
| NCT07810634 | Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab | active not recruiting | — | 200 | Beijing 302 HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)(TAILORx) | active not recruiting | Phase 3 | 10,273 | National Cancer Institute (NCI)NIH | 8 | Sep 8, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials